OS Therapies (NYSE:OSTX) Now Covered by Maxim Group

Maxim Group started coverage on shares of OS Therapies (NYSE:OSTX) in a research note published on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $8.00 price objective on the stock.

A number of other research firms also recently weighed in on OSTX. Brookline Capital Management upgraded shares of OS Therapies to a “strong-buy” rating in a research note on Thursday, August 22nd. EF Hutton Acquisition Co. I upgraded shares of OS Therapies to a “strong-buy” rating in a research note on Tuesday, September 3rd.

OS Therapies Stock Performance

Shares of OS Therapies stock opened at $2.14 on Tuesday. The business has a fifty day moving average of $2.72. OS Therapies has a 1 year low of $1.58 and a 1 year high of $4.90.

Institutional Investors Weigh In On OS Therapies

An institutional investor recently bought a new position in OS Therapies stock. Virtu Financial LLC bought a new stake in OS Therapies Inc (NYSE:OSTX) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 10,045 shares of the company’s stock, valued at approximately $28,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.